JP2023527054A - Ｉ型インターフェロンシグナル伝達の阻害剤による心血管代謝疾患の治療 - Google Patents

Ｉ型インターフェロンシグナル伝達の阻害剤による心血管代謝疾患の治療 Download PDF

Info

Publication number
JP2023527054A
JP2023527054A JP2022572765A JP2022572765A JP2023527054A JP 2023527054 A JP2023527054 A JP 2023527054A JP 2022572765 A JP2022572765 A JP 2022572765A JP 2022572765 A JP2022572765 A JP 2022572765A JP 2023527054 A JP2023527054 A JP 2023527054A
Authority
JP
Japan
Prior art keywords
ifn
patient
type
patients
anifrolumab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022572765A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023527054A5 (cg-RX-API-DMAC10.html
Inventor
シニバルディ，ドミニク
ホワイト，ウェンディ
スミス，マイケル
ケイシー，ケリー
イレイ，ガボール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2023527054A publication Critical patent/JP2023527054A/ja
Publication of JP2023527054A5 publication Critical patent/JP2023527054A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022572765A 2020-05-29 2021-05-28 Ｉ型インターフェロンシグナル伝達の阻害剤による心血管代謝疾患の治療 Pending JP2023527054A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063031854P 2020-05-29 2020-05-29
US63/031,854 2020-05-29
PCT/EP2021/064312 WO2021239928A2 (en) 2020-05-29 2021-05-28 Treatment of cardiometabolic disease

Publications (2)

Publication Number Publication Date
JP2023527054A true JP2023527054A (ja) 2023-06-26
JP2023527054A5 JP2023527054A5 (cg-RX-API-DMAC10.html) 2024-05-30

Family

ID=76269736

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022572765A Pending JP2023527054A (ja) 2020-05-29 2021-05-28 Ｉ型インターフェロンシグナル伝達の阻害剤による心血管代謝疾患の治療

Country Status (10)

Country Link
US (1) US12410254B2 (cg-RX-API-DMAC10.html)
EP (2) EP4157873A2 (cg-RX-API-DMAC10.html)
JP (1) JP2023527054A (cg-RX-API-DMAC10.html)
KR (1) KR20230018446A (cg-RX-API-DMAC10.html)
CN (1) CN115667309A (cg-RX-API-DMAC10.html)
AU (1) AU2021279277A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022023438A2 (cg-RX-API-DMAC10.html)
CA (1) CA3183611A1 (cg-RX-API-DMAC10.html)
IL (1) IL298299A (cg-RX-API-DMAC10.html)
WO (1) WO2021239928A2 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202237647A (zh) * 2020-10-08 2022-10-01 瑞典商阿斯特捷利康公司 狼瘡發作之治療
KR20230110304A (ko) * 2020-11-18 2023-07-21 아스트라제네카 아베 스테로이드 절약
TW202317617A (zh) * 2021-04-23 2023-05-01 瑞典商阿斯特捷利康公司 皮膚紅斑狼瘡之治療
SMT202300382T1 (it) 2021-04-23 2024-01-10 Astrazeneca Ab Regime di dosaggio anti-ifnar1 per iniezione sottocutanea

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170051066A1 (en) * 2015-08-19 2017-02-23 Medimmune, Llc Stable anti-ifnar1 formulation

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003087339A2 (en) 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Spray freeze dry of compositions for pulmonary administration
EP1494651A4 (en) 2002-04-11 2010-10-13 Medimmune Vaccines Inc PRESERVATION OF BIOACTIVE MATERIALS WITH FREEZZED FOAM
JP2006512102A (ja) 2002-04-11 2006-04-13 メディミューン・ヴァクシンズ・インコーポレーテッド 噴霧乾燥による生物活性材料の防腐
US20040042972A1 (en) 2002-04-11 2004-03-04 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration
KR20050088175A (ko) 2002-12-17 2005-09-02 메드이뮨 백신즈 인코포레이티드 생물활성 물질의 고압 분무 건조
NZ545314A (en) * 2003-08-04 2009-03-31 Bristol Myers Squibb Co Methods for treating cardiovascular disease using a soluble CTLA4 molecule
ES2643237T3 (es) 2004-06-21 2017-11-21 E. R. Squibb & Sons, L.L.C. Anticuerpos del receptor 1 de interferón alfa y sus usos
MX2010008578A (es) 2008-02-08 2010-11-10 Medimmune Llc Anticuerpos anti-receptor 1 de interferon alfa con afinidad reducida al ligando fc.
SMT201700063T1 (it) 2009-09-03 2017-03-08 Medimmune Llc Diagnosi di interferoni di tipo 1
CN107110939B (zh) * 2014-09-11 2021-05-14 力保科学公司 用于测定心血管疾病或事件的风险参数的系统
FI20177098A1 (fi) * 2017-08-29 2019-03-01 Leppaeluoto Juhani Menetelmiä ja laitejärjestelyitä diabeteksen, sydän- ja verisuonisairauksien, tulehdusten, dementian ja kuolleisuuden riskejä vähän liikkuvilla henkilöillä vähentävän liikunnan kynnysarvojen määrittämiseen
SG11202101946YA (en) * 2018-09-18 2021-04-29 I Mab Biopharma Hangzhou Co Ltd Anti-ifnar1 antibodies for treating autoimmune diseases
EP3881233A4 (en) * 2018-11-15 2022-11-23 Ampel Biosolutions, LLC DISEASE PREDICTION AND TREATMENT PRIORIZATION WITH MACHINE LEARNING

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170051066A1 (en) * 2015-08-19 2017-02-23 Medimmune, Llc Stable anti-ifnar1 formulation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
2018 ACR/ARHP ANNUAL MEETING[ONLINE],2018, vol. [検索日：2025.05.30], JPN6025024654, pages 975, ISSN: 0005748843 *
ANNALS OF THE RHEUMATIC DISEASES, vol. Vol.75, Supplement 2, JPN6025024652, 2016, pages 293 - 0295, ISSN: 0005748841 *
ANNALS OF THE RHEUMATIC DISEASES, vol. Vol.77, Supplement 2, JPN6025024653, 2018, pages 136 - 137, ISSN: 0005748842 *

Also Published As

Publication number Publication date
BR112022023438A2 (pt) 2022-12-20
WO2021239928A3 (en) 2022-01-27
KR20230018446A (ko) 2023-02-07
WO2021239928A2 (en) 2021-12-02
CA3183611A1 (en) 2021-12-02
CN115667309A (zh) 2023-01-31
IL298299A (en) 2023-01-01
US20240158519A1 (en) 2024-05-16
AU2021279277A1 (en) 2023-02-02
EP4566667A3 (en) 2025-09-03
WO2021239928A9 (en) 2022-03-17
EP4566667A2 (en) 2025-06-11
EP4157873A2 (en) 2023-04-05
US12410254B2 (en) 2025-09-09

Similar Documents

Publication Publication Date Title
Md Yusof et al. Targeting interleukin-6 in rheumatoid arthritis
JP2018109056A (ja) Ｉｌ−４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法
EP4157873A2 (en) Treatment of cardiometabolic disease with inhibitors of type i interferon signalling
EP4306541A2 (en) Anti-ifnar1 dosing regime for subcutaneous injection
NZ794842A (en) Methods of treating inflammatory conditions
JP5834004B2 (ja) ループス治療のための方法および組成物
TW202133877A (zh) 全身性紅斑狼瘡中之ｉ型干擾素抑制
JP2023546361A (ja) ループスにおける紅斑の治療
JP2025000638A (ja) 抗ＩＦＮ－α／ω抗体の投与方法
US20240368294A1 (en) Cd40l-specific tn3-derived scaffolds for use in the treatment and prevention of rheumatoid arthritis
JP7475011B2 (ja) Ｈｔｌｖ－１関連脊髄症（ｈａｍ）治療又は予防剤、及びｈａｍの治療方法
AU2022274306A9 (en) Inhibitor of type 1 interferon receptor steroid sparing in systemic lupus erythematosus patients
US20220267428A1 (en) BLOCKADE OF RGMb FOR TREATING INFLAMMATORY BOWEL DISEASE AND COLITIS
Cohen et al. Safety, tolerability, pharmacokinetic and pharmacodynamic properties of SBI-087, a CD20-directed B-cell depleting agent: phase 1 dose escalating studies in patients with either mild rheumatoid arthritis or systemic lupus
EP4161576A1 (en) Method of treating or preventing acute respiratory distress syndrome
JP6923594B2 (ja) Ｉｌ−４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法
CN121127499A (zh) 狼疮的治疗
JP2026513830A (ja) 用量
TW202430212A (zh) 狼瘡之治療
HK40076109A (en) Methods for treating or preventing asthma by administering an il-4r antagonist
HK40076109B (en) Methods for treating or preventing asthma by administering an il-4r antagonist
HK40006965B (en) Methods for treating or preventing asthma by administering an il-4r antagonist
HK40006965A (en) Methods for treating or preventing asthma by administering an il-4r antagonist

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20231222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240521

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240521

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250617

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251209